ClinicalTrials.gg
CompletedNCT04666610EXPANDUpdated Oct 30, 2026

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

A Phase 3 interventional study of Brivaracetam and Placebo in Childhood Absence Epilepsy and Juvenile Absence Epilepsy, sponsored by UCB Biopharma SRL. Completed at 35 sites in 7 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Updated Oct 30, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
2 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Epilepsy, Absence with a site in United States — 1 open to participants now, 2 under way, 2 of them phase 3. Epilepsy, Absence · United States.

Enrollment
2nd of 11
154 · median 40
Started
2021
the only one that year
Phase 3
5 of 16
1 open now
Registered
10th of 16
by date
Lead sponsor
3 of 16
UCB Biopharma SRL

Among the 16 studies in Epilepsy, Absence with a site in United States, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2021, is one of 5 in phase 3, and was the 10th registered.

Epilepsy, Absence

24 studies on the registry are indexed under Epilepsy, Absence; 2 are open to participants now.

Browse Epilepsy, Absence studies →

Open to participants now

1 of the 16 studies in Epilepsy, Absence with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Epilepsy, Absence studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 2 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Epilepsy, Absence with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

03

Conditions studied

  • Childhood Absence Epilepsy
  • Juvenile Absence Epilepsy

Keywords

  • Brivaracetam
  • Briviact
  • Epilepsy
  • Childhood absence Epilepsy
  • Juvenile absence epilepsy
  • CAE
  • JAE
04

Who can participate

Ages eligible
2 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant is 2 to 25 years of age inclusive, at the time of signing the . No study participants from 2 to \<4 years of age will be included in Stage 1
  • Study participant is diagnosed with either childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE) as defined by the International League Against Epilepsy (ILAE) criteria
  • Study participants 2 to \<4 years of age and participants who had onset of absence seizures at an age younger than 4 years must have a negative glucose transporter type 1 deficiency syndrome (GLUT1DS) genetic test
  • Study participant is untreated with antiepileptic drugs (AEDs) or pretreated for absence seizures with a maximum of 2 historical AEDs, but without AED treatment for a period of at least 5 half-lives of the AED before randomization into this study. The UCB study physician should be consulted if in doubt
  • Study participant has electroencephalogram (EEG) evidence of bilateral synchronous, symmetric generalized paroxysmal spike waves (2.5-6 hertz) with normal background activity and with at least 1 electrographically recorded seizure lasting 3 seconds or more on a 1-hour EEG with hyperventilation (HV) while awake at Visit 1 (V1), or on a historical EEG up to 12 weeks before enrollment
  • Study participant has a history of clinically evident absence seizures occurring on at least 3 days per week in the 2 weeks prior to enrollment
  • Study participant is without treatment with psychoactive drugs or on a stable dose for at least 2 weeks prior to randomization
  • Study participant has normal neurological examination, head size, development and cognition
  • Body weight is more than or equal to 9 kg
  • Male and female

    a) A sexually active male study participant must agree to use during the treatment period and for at least 2 days, corresponding to the time needed to eliminate study treatment, after the last dose of study treatment and refrain from donating sperm during this period b) A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: The study participant is premenarchial OR A woman of (WOCBP) who agrees to follow the contraceptive guidance during the treatment period and for at least 2 days after the last dose of study treatment, corresponding to the time needed to eliminate study treatment

  • Study participant provides consent/assent, and the study participant's parent/legal representative/caregiver provides signed informed consent for minor study participants, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion criteria

Exclusion Criteria:

  • Study participant has a history of nonfebrile seizures other than absence seizures (eg, generalized tonic-clonic seizures or myoclonic seizures)
  • Study participant has a history of absence status epilepticus
  • Study participant has a history or presence of paroxysmal nonepileptic seizures
  • Study participant has a (ECG) abnormality in the opinion of the Principal Investigator
  • Study participant has hepatic impairment ( Score A, B, or C) based on the Investigator's assessment
  • Study participant has a history of major psychiatric disease or any clinically significant medical condition that would preclude appropriate study participation
  • Study participant has active suicidal ideation prior to study entry as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS; for study participants 6 years or older) or clinical judgement (for study participants younger than 6 years). The study participant should be referred immediately to a Mental Healthcare Professional
  • Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt). The study participant should be immediately evaluated by a Mental Healthcare Professional to address safety concerns
  • Study participant with known fructose intolerance or of any of the ingredients in brivaracetam oral solution
  • Study participant has end-stage kidney disease requiring dialysis
  • Concomitant use of rifampicin/rifampin; prior use must have been stopped at least 2 months before randomization
  • Concomitant use of strong CYP2C19 inhibitors like fluconazole, fluoxetine and fluvoxamine, prior use must have been stopped at least 1 week before randomization
  • Study participant has participated in another study of an medicinal product (IMP; and/or an investigational device) within the previous 30 days prior to
  • Study participant has clinical or EEG findings not consistent with a diagnosis of childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Brivaracetam 200 mg

    Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to brivaracetam (BRV) 200mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period.

    Drug: Brivaracetam

  • Experimental
    Placebo to 200 mg brivaracetam

    Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to 'placebo to BRV 200mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 200mg/day (or equivalent dose) during the AT period.

    Drug: Brivaracetam · Other: Placebo

  • Experimental
    Brivaracetam 100 mg

    Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to BRV 100mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period.

    Drug: Brivaracetam

  • Experimental
    Placebo to 100 mg brivaracetam

    Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 1: Study participants randomized to 'placebo to BRV 100mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 100mg/day (or equivalent dose) during the AT period.

    Drug: Brivaracetam · Other: Placebo

  • Experimental
    Optimal dose of BRV (defined following Stage 1)

    Placebo-Controlled (PC) and Active Treatment Period (AT): Stage 2: Study participants will be randomized in Stage 2 to receive a fixed dose of the optimal dose of brivaracetam (defined following Stage 1). Study participants randomized to the BRV optimal dose will receive this dose during the 2-week PC period and subsequent 11-week AT period.

    Drug: Brivaracetam

  • Experimental
    Placebo to BRV optimal dose (defined following Stage 1)

    Placebo-Controlled (PC) and Active Treatment (AT) Period: Stage 2: Study participants will be randomized in Stage 2 of the study to 'placebo to BRV optimal dose'. Study participants randomized to placebo to brivaracetam (BRV) optimal dose will receive placebo during the PC period followed by BRV optimal dose during the AT period.

    Drug: Brivaracetam · Other: Placebo

  • Experimental
    Brivaracetam received during RDW

    Randomized Withdrawal (RDW) Period: Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Participants who are randomized to this arm will continue on the Brivaracetam dose they were receiving in the AT period.

    Drug: Brivaracetam

  • Experimental
    Placebo received during RDW

    Randomized Withdrawal (RDW) Period: Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Study participants who are randomized to the placebo arm in the RDW Period will be tapered down to 0 mg and receive 0 mg for 2 weeks.

    Drug: Brivaracetam · Other: Placebo

Interventions

  • * Pharmaceutical form: Oral solution * Route of administration: Oral use Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.

    Also known as: BRV

  • OtherPlacebo

    Subjects will receive placebo at pre-specified time-points to maintain the blinding.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of participants who met the criteria for absence seizure freedom within 4 days prior to or during the 24-hour ambulatory electroencephalogram (EEG) at Day 14

    A 24-hour ambulatory electroencephalogram (EEG) will be performed at day 14. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include hyperventilation as a standard provocation test at the beginning of the EEG. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.

    Time frame: Day 14

Secondary outcomes

  1. Percentage of participants who met the criteria for absence seizure freedom during the randomized withdrawal (RDW) period as determined by electroencephalogram (EEG)

    Study participants (or their care givers) who believe they are experiencing a recurrence of absence seizures will contact the clinical site for a 1-hour EEG (with hyperventilation (HV)). If no absence seizure is observed during this 1hr EEG (locally read), the study participant will receive a 24-hour ambulatory EEG. If an absence seizure is observed during either EEG, the study participant will be considered as not Absence seizure free and leave the study. If no absence seizures are determined by 1/24hr ambulatory EEG the participant will conduct a 24-hour EEG at week 17. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include HV as a standard provocation test at the beginning of the EEG.

    Time frame: From Week 13 to Week 17

  2. Percent change from Baseline to Day 14 in number of absence seizures on 24-hour ambulatory electroencephalogram (EEG)

    A 24-hour ambulatory electroencephalogram (EEG) will be performed at baseline and day 14. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include hyperventilation as a standard provocation test at the beginning of the EEG. This endpoint is the difference between the number of seizures at baseline and Day 14.

    Time frame: From Baseline to Day 14

  3. Percentage of participants who met the criteria for absence seizure freedom based on diary during the 4 days prior to the visit at Day 14

    During the study subjects will keep a diary to record daily seizure activity from Visit 1 until end of the randomized withdrawal (RDW) Period. Each seizure type experienced will be recorded. The last 4 study days prior to Day 14 EEG are used for this endpoint. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.

    Time frame: Day 14

  4. Percentage of participants who met the criteria for absence seizure freedom on 24-hour ambulatory electroencephalogram (EEG) at Week 12

    A 24-hour ambulatory electroencephalogram (EEG) will be performed at day 14. The awake hours from the EEG will be analyzed for absence seizures. Every 24-hour EEG will include hyperventilation as a standard provocation test at the beginning of the EEG. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.

    Time frame: Week 12

  5. Percentage of participants who met the criteria for absence seizure freedom based on diary during the 4 days prior to the visit at Week 12

    During the study subjects will keep a diary to record daily seizure activity from Visit 1 until end of the randomized withdrawal (RDW) Period. Each seizure type experienced will be recorded. The last 4 study days prior to Week 12 EEG are used for this endpoint. Patient will be regarded as not meeting the criteria for absence seizure freedom if they received benzodiazepine in the 4 days prior to the EEG or during the EEG.

    Time frame: Week 12

  6. Percentage of participants with treatment-emergent adverse events (TEAEs) during the study

    An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP).

    Time frame: From Day 1 until End of Safety Follow-Up (up to Week 23)

  7. Percentage of participants with treatment-emergent adverse events (TEAEs) leading to discontinuation of study treatment

    An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP).

    Time frame: From Day 1 until End of Down Titration Period (up to Week 21)

  8. Percentage of participants with serious adverse events (SAEs) during the study

    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization * Is a congenital anomaly or birth defect * Results in permanent or significant disability/incapacity * Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

    Time frame: From Screening Period (Day -14 to Day -2) until End of Safety Follow-Up (up to Week 23)

  9. Percentage of participants with drug-related treatment-emergent adverse events (TEAEs) during the study

    An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP). 'Drug related AEs' are the subset of AEs that the investigator considers as related to the study drug.

    Time frame: From Baseline (Day -1) until End of Safety Follow-Up (up to Week 23)

07

Study locations

35 sites
  • N01269 115
    Birmingham, Alabama 35233, United States
  • N01269 105
    Orange, California 92868-3874, United States
  • N01269 116
    Denver, Colorado 80202, United States
  • N01269 111
    Miami, Florida 33155-3009, United States
  • N01269 101
    Tampa, Florida 33612, United States
  • N01269 104
    Winter Park, Florida 32789, United States
  • N01269 110
    Augusta, Georgia 30912, United States
  • N01269 100
    New Brunswick, New Jersey 08901, United States
  • N01269 109
    Winston-Salem, North Carolina 27109, United States
  • N01269 106
    Philadelphia, Pennsylvania 19134, United States
  • N01269 400
    Tbilisi, Georgia
  • N01269 401
    Tbilisi, Georgia
  • N01269 402
    Tbilisi, Georgia
  • N01269 403
    Tbilisi, Georgia
  • N01269 405
    Tbilisi, Georgia
  • N01269 323
    Messina, Italy
  • N01269 321
    Milan, Italy
  • N01269 324
    Milan, Italy
  • N01269 320
    Pavia, Italy
  • N01269 322
    Roma, Italy
  • N01269 325
    Roma, Italy
  • N01269 326
    Verona, Italy
  • N01269 562
    Bucharest, Romania
  • N01269 563
    Bucharest, Romania
  • N01269 560
    Iași, Romania
  • N01269 561
    Timişoara, Judeţ Timiş, Romania
  • N01269 632
    Bardejov, Slovakia
  • N01269 630
    Dubnica nad Váhom, Slovakia
  • N01269 631
    Nové Zámky, Slovakia
  • N01269 354
    Terrassa, Spain
  • N01269 600
    Dnipro, Ukraine
  • N01269 601
    Dnipro, Ukraine
  • N01269 604
    Kharkiv, Ukraine
  • N01269 607
    Uzhhorod, Ukraine
  • N01269 602
    Vinnytsia, Ukraine
08

References and documents

Publications

  • Bast T, Schulz AL, Floricel F, Morita D, Cleveland JM, Elshoff JP. Efficacy and tolerability of brivaracetam monotherapy in childhood and juvenile absence epilepsy: An innovative adaptive trial design. Epilepsia Open. 2022 Dec;7(4):588-597. doi: 10.1002/epi4.12628. Epub 2022 Aug 4. PubMed 35844134 ↗

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Jul 2026, 59 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2020
First posted
Dec 14, 2020
StartActual
Jul 29, 2021
Primary completionActual
Jul 7, 2026
CompletionActual
Jul 7, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
153→154
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Enrollment 153→154
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04666610
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Dec 14, 2020
Start date
Jul 29, 2021
Primary completion
Jul 7, 2026
Completion
Jul 7, 2026
Last update
Oct 30, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion